在健康·生活领域中，中国科研团队的最新研究成果为肾细胞癌（RCC）的早期诊断和精准治疗提供了新的策略。这则消息由中新社记者陈静报道，发布于2024年7月26日。研究团队，由上海交通大学医学院附属仁济医院的郑军华、翟炜团队和上海交通大学生物医学工程学院的钱昆团队共同合作完成，他们的研究成果发表在国际知名期刊《Advanced Science》上。
肾细胞癌是最常见的且具有高致死率的肾癌类型。面对术后5年内约20%至25%的复发和转移风险，开发新型简便的监测工具显得尤为重要。有效的管理，包括肿瘤良恶性判断、早期诊断和预后评估，对改善患者生存结果至关重要，有助于提高5年生存率并指导临床干预。然而，现有的临床方法在识别小肿瘤、区分良恶性病例和优化流程方面存在挑战，缺乏有效的生物标志物和预后评估工具也限制了治疗策略的制定。
研究团队创新性地开发了一种基于血清和尿液代谢、指纹代谢图谱的分析方法，利用机器学习成功对肾肿瘤进行亚型分类、早期诊断和预后评估。他们还构建了一个预测模型，用于疾病预测，显示出显著的效果。这一研究不仅为代谢分析工具在RCC中的应用提供了前景，也为肾脏肿瘤的早期诊断和精准治疗提供了新的策略。
这一成果的发布，不仅展示了中国科研团队在代谢生物学领域的重要进展，也为全球医学界在肾细胞癌研究领域提供了新的思路和方法。通过整合血清和尿液的综合分析，这一方法有望识别出具有临床价值的潜在生物标志物，从而进一步提高RCC的诊断准确性和治疗效果。
这一研究的发布，不仅对中国的医学研究领域产生了积极影响，也为全球医学界在肾细胞癌的早期诊断和精准治疗方面提供了新的视角和可能性。
英语如下：
News Title: “Chinese Innovation: Serum Urine Metabolic Maps Pave New Path for Early Kidney Cancer Diagnosis and Precision Treatment”
Keywords: Kidney Cancer Diagnosis, Precision Treatment, Early Monitoring
News Content: In the realm of Health & Lifestyle, the latest research breakthrough by a Chinese scientific team offers new strategies for early diagnosis and precision treatment of Renal Cell Carcinoma (RCC). This news was reported by Xinhua News Agency’s Chen Jing, published on July 26, 2024. The research, a collaborative effort between teams led by Zheng Junhua and Zhai Wei from Rui Jin Hospital affiliated with Shanghai Jiao Tong University Medical School, and Qian Kun from the Department of Biomedical Engineering, Shanghai Jiao Tong University, was published in the internationally renowned journal, Advanced Science.
Renal Cell Carcinoma is one of the most prevalent and lethal types of kidney cancer, with a significant risk of recurrence and metastasis within 5 years post-surgery. The development of novel, efficient monitoring tools is thus of paramount importance. Effective management, including tumor malignancy assessment, early diagnosis, and prognosis evaluation, is crucial for improving patient survival outcomes, enhancing the 5-year survival rate, and guiding clinical interventions. However, existing clinical methods face challenges in identifying small tumors, distinguishing benign from malignant cases, and optimizing processes, with a lack of effective biomarkers and prognosis assessment tools limiting treatment strategy formulation.
The research team innovatively developed an analysis method based on serum and urine metabolomics and fingerprint metabolomics, utilizing machine learning to successfully classify, diagnose, and assess the prognosis of renal tumors. They also constructed a predictive model for disease prediction, showing remarkable effectiveness. This study not only promises a future for metabolomics tools in RCC, but also provides new strategies for early diagnosis and precision treatment of renal tumors.
The publication of this achievement not only highlights significant advancements in metabolic biology by Chinese research teams, but also opens new avenues for the global medical community in RCC research. By integrating the comprehensive analysis of serum and urine, this method has the potential to identify clinically valuable biomarkers, thereby significantly enhancing the diagnostic accuracy and treatment efficacy of RCC.
The release of this study has a positive impact on China’s medical research field, offering new perspectives and possibilities for global medical communities in the early diagnosis and precision treatment of renal cell carcinoma.
【来源】http://www.chinanews.com/life/2024/07-26/10257877.shtml
Views: 5